- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
- Interventions
- Biospecimen Collection, Extended Release Metformin Hydrochloride, Monitoring, Nutritional Assessment, Short-Term Fasting
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alcohol Use Disorder, Alcohol Drinking, Alcohol Abuse, Alcohol Dependence
- Interventions
- Contingency Management, Computer Based Training for Cognitive Behavioral Therapy for AUD (CBT4CBT)
- Behavioral
- Lead sponsor
- Washington State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Long COVID
- Interventions
- RNA Biomarker Blood Test
- Diagnostic Test
- Lead sponsor
- MaxWell Clinic, PLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Brentwood, Tennessee
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
- Interventions
- Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Low Birth Weight, Small for Gestational Age, Immunodeficiency
- Interventions
- Cord blood collection for analysis
- Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Up to 2 Hours
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Peripheral Arterial Disease
- Interventions
- Beetroot juice, Beetroot juice placebo
- Drug
- Lead sponsor
- David N. Proctor, PhD
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Breast Carcinoma
- Interventions
- Biospecimen Collection, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma, Very High Risk Prostate Carcinoma
- Interventions
- 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy, Prostate Tissue Collection, Single-photon emission computed tomography (SPECT)/Computerized tomography (CT), Blood Sample Collection
- Drug · Procedure
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Melanoma
- Interventions
- Blood Sample, Tumor Sample
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
- Diagnostic Test · Behavioral
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 10 Years to 37 Years
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Opioid Pain Medication
- Interventions
- Tranexamic acid, Aminocaproic acid, Recombinant Human Thrombin, Lidocaine Hydrochloride with Epinephrine, Bupivacaine Hydrochloride with Epinephrine
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Covid19, Echocardiography, Ultrasound
- Interventions
- Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound
- Diagnostic Test
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Interventions
- Short course radiation, Active Surveillance
- Radiation · Other
- Lead sponsor
- University of Vermont Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
- Interventions
- Short-Term Fasting, Chemotherapy, Biospecimen Collection, Questionnaire Administration
- Other · Drug · Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Cherry Hill, New Jersey • Sewell, New Jersey • Philadelphia, Pennsylvania + 1 more
- Conditions
- Breast Cancer
- Interventions
- Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes, Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a), Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12), Patient Reported Outcomes PROMIS, Patient Reported Outcomes FACT-Endocrine Symptoms, Patient Reported Outcomes Penn Arthralgia Aging Survey, Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE), p16 tumor suppressor gene
- Behavioral · Diagnostic Test
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Japanese Encephalitis
- Interventions
- Blood draw, IC51 has given in the parent study IC51-322
- Procedure · Biological
- Lead sponsor
- Valneva Austria GmbH
- Industry
- Eligibility
- 9 Months to 20 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- HIV Infections
- Interventions
- Kaletra (lopinavir/ritonavir), buprenorphine, Clinical evaluations/Blood draws
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Kidney Transplant Rejection
- Interventions
- Diagnostic Test: TruGraf® Testing
- Diagnostic Test
- Lead sponsor
- Transplant Genomics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Anovulation, FHA, Eumenorrhea, Polycystic Ovary Syndrome
- Interventions
- Screening evaluation, Meal Response, Blood Collection, Functional MRI, Endocrine Assessment
- Procedure · Genetic
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Infections, Meningococcal
- Interventions
- Nimenrix, Blood sampling
- Biological · Procedure
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 15 Years to 30 Years
- Enrollment
- 818 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 10
- States / cities
- Daly City, California • Fairfield, California • Redwood City, California + 6 more
- Conditions
- Neuroblastoma Survivors
- Interventions
- Urine sample
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 20 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- laboratory biomarker analysis, fertility assessment and management, management of therapy complications, ultrasound imaging
- Other · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 14 Years to 35 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hodgkin Lymphoma
- Interventions
- Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, Ophthalmology Examination
- Other · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Transthyretin Amyloidosis, Amyloidosis, Leptomeningeal, Transthyretin-Related
- Interventions
- Tolcapone
- Drug
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts